Table 1.
Comparison of baseline characteristics between the high- and low-CXI groups
| Characteristic | LD | ED | ||||
|---|---|---|---|---|---|---|
| High-CXI group (n = 83) | Low-CXI group (n = 24) | p | High-CXI group (n = 123) | Low-CXI group (n = 37) | p | |
| Age | 0.067 | 0.214 | ||||
| < 70 years | 52 (62.7%) | 10 (41.7%) | 69 (56.1%) | 25 (67.6%) | ||
| ≥ 70 years | 31 (37.4%) | 14 (58.3%) | 54 (43.9%) | 12 (32.4%) | ||
| Median (IQR), years | 66 (61–71) | 70.5 (66–76.5) | 0.033 | 68 (61–74) | 68 (64–71) | 0.754 |
| ECOG PS | 0.008 | 0.013 | ||||
| 0–1 | 74 (89.2%) | 16 (66.7%) | 98 (79.7%) | 22 (59.5%) | ||
| 2–3 | 9 (10.8%) | 8 (33.3%) | 25 (20.3%) | 15 (40.5%) | ||
| Smoking status | 0.400 | > 0.998 | ||||
| Never-smoker | 1 (1.2%) | 1 (4.2%) | 2 (1.6%) | 0 (0.0%) | ||
| Current/former smoker | 82 (98.8%) | 23 (95.8%) | 121 (98.4%) | 37 (100.0%) | ||
| Regimen | 0.224 | 0.242 | ||||
| Etoposide and platinum | 83 (100.0%) | 23 (95.8%) | 114 (92.7%) | 32 (86.5%) | ||
| Irinotecan and cisplatin | 0 (0.0%) | 1 (4.2%) | 9 (7.3%) | 5 (13.5%) | ||
| Prophylactic cranial irradiation | 0.132 | 0.006 | ||||
| Yes | 49 (59.0%) | 10 (41.7%) | 50 (40.7%) | 6 (16.2%) | ||
| No | 34 (41.0%) | 14 (58.3%) | 73 (59.4%) | 31 (83.8%) | ||
| Lactate dehydrogenase status (n = 72 in LD, n = 133 in ED) | 0.339 | 0.474 | ||||
| Normal | 31 (57.4%) | 8 (44.4%) | 34 (34.0%) | 9 (27.3%) | ||
| Elevated | 23 (42.6%) | 10 (55.6%) | 66 (66.0%) | 24 (72.7%) | ||
| Median BMI (IQR), kg/m2 | 23.0 (20.8–25.2) | 21.9 (20.1–23.8) | 0.104 | 22.6 (20.7–24.5) | 21.0 (19.9–22.5) | 0.007 |
LD limited-stage disease, ED extensive-stage disease, CXI cachexia index, IQR interquartile range, ECOG PS Eastern Cooperative Oncology Group performance status, BMI body mass index